Department of Obstetrics & Gynecology, Vita-Salute San Raffaele University, School of Medicine at San Raffaele Scientific Institute, Via Olgettina 60, 20132 Milano, Italy.
J Clin Virol. 2011 Aug;51(4):250-4. doi: 10.1016/j.jcv.2011.05.017. Epub 2011 Jun 15.
Human Papillomavirus (HPV) is the leading cause of cervical cancer among women. Immunosuppression is recognized as one of the major risk factors for HPV infection and persistence.
Aim of this study was to determine if solid organs (24 kidney and 24 kidney/pancreas) transplanted Italian women undergoing immunosuppressive therapies were at higher risk of HPV genital infection and cervical precancerous lesions in a ten-year follow-up.
Forty-eight women that underwent transplant from 1990 to 2000, receiving multi-drug immunosuppressive therapy, were enrolled prospectively in a long-term follow-up protocol. Patients were cytologically (Pap smear) and virologically (HPV-DNA test) tested each year for 10 years. Incidence of HPV-DNA positivity and of cervical cytological/histological abnormalities was collected. Results were statistically analyzed and compared to a matching control group of 200 healthy women.
HPV-DNA positivity and cytological High-Grade (HG-SIL) cervical lesions did not show statistically significant differences in cases compared to controls, while statistical significance was observed in Low-Grade (LG-SIL) cytological diagnoses. No statistically significant difference was observed in histology-proven cervical lesions.
Women receiving immunosuppression therapy following transplant do not seem to require intensive follow-up, and should not be considered a high-risk subgroup, as they do not show a statistically significant higher incidence of HPV infections or high-grade cervical dysplasia compared to healthy immunocompetent matching controls.
人乳头瘤病毒(HPV)是女性宫颈癌的主要病因。免疫抑制被认为是 HPV 感染和持续存在的主要危险因素之一。
本研究旨在确定接受免疫抑制治疗的意大利女性实体器官(24 例肾移植和 24 例肾/胰移植)移植后是否存在 HPV 生殖器感染和宫颈癌前病变的风险增加,并在十年的随访中进行评估。
48 例女性于 1990 年至 2000 年期间接受多药物免疫抑制治疗进行移植,前瞻性纳入长期随访方案。患者每年进行细胞学(巴氏涂片)和病毒学(HPV-DNA 检测)检查,共进行 10 年。收集 HPV-DNA 阳性和宫颈细胞学/组织学异常的发生率。结果进行统计学分析,并与 200 例健康女性的匹配对照组进行比较。
HPV-DNA 阳性和细胞学高级别(HG-SIL)宫颈病变在病例组与对照组之间未显示出统计学显著差异,而在低级别(LG-SIL)细胞学诊断中观察到统计学显著差异。组织学证实的宫颈病变无统计学显著差异。
接受移植后免疫抑制治疗的女性似乎不需要进行强化随访,并且不应被视为高风险亚组,因为与健康免疫功能正常的匹配对照组相比,她们的 HPV 感染或高级别宫颈发育不良的发生率没有统计学显著增加。